SUO 3001
Alternative Names: SUO-3001Latest Information Update: 12 Sep 2023
At a glance
- Originator Suono Bio
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Crohn's disease
Most Recent Events
- 12 Sep 2023 SUO 3001 is available for licensing as of 12 Sep 2023. https://www.suonobio.com/tech--pipeline.html
- 25 Feb 2022 Preclinical trials in Crohn's disease in USA (Intradermal) before February 2022 (Suono Bio pipeline, February 2022)
- 25 Feb 2022 Suono-Bio plans a pre-IND meeting with the US FDA for Crohn's disease (Suono Bio pipeline, February 2022)